A Introduction to Neurological Infections: Neuro-infectious Disease as Part of Neuroimmunology

  • Andrew R. Pachner


Neurological infections are an important part of neuroimmunology. The concepts and issues dealt with in the previous chapters have covered neurological inflammatory diseases that are considered “autoimmune” primarily because no pathogen has yet been identified. These diseases also have relevance to neurological inflammatory diseases in which pathogens have been identified. The nervous system has only a limited repertoire with respect to inflammation. Processes such as microglial proliferation, loss of blood–brain barrier function, immune cell infiltration into the CNS, have already been discussed and function similarly in neurological infections as they do in autoimmune diseases.


Human Immunodeficiency Virus West Nile Virus Progressive Multifocal Leukoencephalopathy Bacterial Meningitis Varicella Zoster Virus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Pachner AR. Lyme disease. Trends Neurosci. 1989;12(5):177–81.PubMedCrossRefGoogle Scholar
  2. 2.
    Scheld WM, Whitley RJ, Marra CM, editors. Infections of the central nervous system. 3rd ed. Philadelphia: Lippincott-Williams; 2004.Google Scholar
  3. 3.
    Roos KL, editor. Principles of neurologic infectious diseases. New York: McGraw-Hill; 2005.Google Scholar
  4. 4.
    Pachner AR, Dail D, Bai Y, et al. Genotype determines phenotype in experimental Lyme borreliosis. Ann Neurol. 2004;56(3):361–70.PubMedCrossRefGoogle Scholar
  5. 5.
    Pachner AR, Basta J, Delaney E, Hulinska D. Localization of Borrelia burgdorferi in murine Lyme borreliosis by electron microscopy. Am J Trop Med Hyg. 1995;52(2):128–33.PubMedGoogle Scholar
  6. 6.
    Kaiser R. Intrathecal immune response in patients with neuroborreliosis: specificity of antibodies for neuronal proteins. J Neurol. 1995;242(5):319–25.PubMedCrossRefGoogle Scholar
  7. 7.
    Clark JR, Carlson RD, Sasaki CT, Pachner AR, Steere AC. Facial paralysis in Lyme disease. Laryngoscope. 1985;95(11):1341–5.PubMedGoogle Scholar
  8. 8.
    Pachner AR, Steere AC. The triad of neurologic manifestations of Lyme disease: meningitis, cranial neuritis, and radiculoneuritis. Neurology. 1985;35(1):47–53.PubMedGoogle Scholar
  9. 9.
    Hansen K, Lebech AM. The clinical and epidemiological profile of Lyme neuroborreliosis in Denmark 1985-1990. A prospective study of 187 patients with Borrelia burgdorferi specific intrathecal antibody production. Brain. 1992;115(Pt 2):399–423.PubMedCrossRefGoogle Scholar
  10. 10.
    Steere AC, Pachner AR, Malawista SE. Neurologic abnormalities of Lyme disease: successful treatment with high-dose intravenous penicillin. Ann Intern Med. 1983;99(6):767–72.PubMedGoogle Scholar
  11. 11.
    Ljostad U, Skogvoll E, Eikeland R, et al. Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised trial. Lancet Neurol. 2008;7(8):690–5.PubMedCrossRefGoogle Scholar
  12. 12.
    van de Beek D, de Gans J, Tunkel AR, Wijdicks EF. Community-acquired bacterial meningitis in adults. N Engl J Med. 2006;354(1):44–53.PubMedCrossRefGoogle Scholar
  13. 13.
    Jarvis JN, Harrison TS. HIV-associated cryptococcal meningitis. AIDS. 2007;21(16):2119–29.PubMedCrossRefGoogle Scholar
  14. 14.
    Be NA, Kim KS, Bishai WR, Jain SK. Pathogenesis of central nervous system tuberculosis. Curr Mol Med. 2009;9(2):94–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Anderson NE, Willoughby EW. Chronic meningitis without predisposing illness – a review of 83 cases. Q J Med. 1987;63(240):283–95.PubMedGoogle Scholar
  16. 16.
    Savarin C, Bergmann CC. Neuroimmunology of central nervous system viral infections: the cells, molecules and mechanisms involved. Curr Opin Pharmacol. 2008;8(4):472–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Pessach I, Walter J, Notarangelo LD. Recent advances in primary immunodeficiencies: identification of novel genetic defects and unanticipated phenotypes. Pediatr Res. 2009;65(5 Pt 2):3R–12.PubMedCrossRefGoogle Scholar
  18. 18.
    Skoldenberg B, Forsgren M, Alestig K, et al. Acyclovir versus vidarabine in herpes simplex encephalitis. Randomised multicentre study in consecutive Swedish patients. Lancet. 1984;2(8405):707–11.PubMedCrossRefGoogle Scholar
  19. 19.
    Whitley RJ, Alford CA, Hirsch MS, et al. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med. 1986;314(3):144–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Singer EJ, Valdes-Sueiras M, Commins D, Levine A. Neurologic presentations of AIDS. Neurol Clin. 2010;28(1):253–75.PubMedCrossRefGoogle Scholar
  21. 21.
    Robertson KR, Su Z, Margolis DM, et al. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology. 2010;74(16):1260–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(4):251–61.PubMedCrossRefGoogle Scholar
  23. 23.
    Tan K, Roda R, Ostrow L, McArthur J, Nath A. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology. 2009;72(17):1458–64.PubMedCrossRefGoogle Scholar
  24. 24.
    Gyure KA. West Nile Virus Infections. J Neuropathol Exp Neurol. 2009;68(10):1053–60.PubMedCrossRefGoogle Scholar
  25. 25.
    Lipton HL. Human Vilyuisk encephalitis. Rev Med Virol. 2008;18(5):347–52.PubMedCrossRefGoogle Scholar
  26. 26.
    Bleharski JR, Li H, Meinken C, et al. Use of genetic profiling in leprosy to discriminate clinical forms of the disease. Science. 2003;301(5639):1527–30.PubMedCrossRefGoogle Scholar
  27. 27.
    Steiner I, Kennedy PG, Pachner AR. The neurotropic herpes viruses: herpes simplex and varicella-zoster. Lancet Neurol. 2007;6(11):1015–28.PubMedCrossRefGoogle Scholar
  28. 28.
    Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402–15.PubMedCrossRefGoogle Scholar
  29. 29.
    Cohen BA. Neurologic manifestations of toxo­plasmosis in AIDS. Semin Neurol. 1999;19(2):201–11.PubMedCrossRefGoogle Scholar
  30. 30.
    Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 2010;9(4):425–37.PubMedCrossRefGoogle Scholar
  31. 31.
    Marra CM. Update on neurosyphilis. Curr Infect Dis Rep. 2009;11(2):127–34.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Andrew R. Pachner
    • 1
  1. 1.Department of Neurology and Neuroscience New Jersey Medical SchoolUniversity of Medicine and Dentistry of New JerseyNewarkUSA

Personalised recommendations